| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ECM1 |
| Uniprot No | Q16610 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 386-540aa |
| 氨基酸序列 | HPPSPTRDECFARRAPYPNYDRDILTIDIGRVTPNLMGHLCGNQRVLTKHKHIPGLIHNMTARCCDLPFPEQACCAEEEKLTFINDLCGPRRNIWRDPALCCYLSPGDEQVNCFNINYLRNVALVSGDTENAKGQGEQGSTGGTNISSTSEPKEE |
| 预测分子量 | 52.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与ECM1重组蛋白相关的代表性文献概览：
1. **"Extracellular matrix protein 1 (ECM1) regulates skin angiogenesis and tumor progression"**
- **作者**: Mongkolsapaya et al. (2005)
- **摘要**: 研究揭示了重组ECM1蛋白通过调控血管生成因子(如VEGF)促进皮肤血管生成，并与黑色素瘤的侵袭和转移相关。
2. **"ECM1 interacts with fibulin-3 to control extracellular matrix assembly"**
- **作者**: Hulleberg et al. (2018)
- **摘要**: 通过重组ECM1蛋白的体外实验，发现其与fibulin-3蛋白互作，共同调节细胞外基质的结构稳定性，影响组织修复和纤维化疾病进程。
3. **"Recombinant ECM1 suppresses T cell activation in autoimmune disorders"**
- **作者**: Chen et al. (2020)
- **摘要**: 利用大肠杆菌表达系统制备重组ECM1蛋白，证明其可通过抑制NF-κB信号通路减轻类风湿性关节炎模型中的炎症反应。
*注：以上文献信息为模拟概括，实际引用需根据具体研究通过PubMed或Web of Science检索确认。如需精确文献，建议补充研究领域细分(如肿瘤、免疫或结构生物学方向)。*
**Background of Recombinant ECM1 Protein**
The extracellular matrix protein 1 (ECM1) is a secreted glycoprotein encoded by the *ECM1* gene, first identified in 1994. Structurally, ECM1 contains conserved cysteine-rich domains, including a CC motif and tandem repeats, which facilitate interactions with extracellular matrix (ECM) components like perlecan, fibulin, and laminin. It plays critical roles in tissue homeostasis, angiogenesis, and cell adhesion, with significant involvement in skin differentiation, bone remodeling, and vascular development.
ECM1 exists in multiple splice variants (e.g., ECM1a, ECM1b), each exhibiting tissue-specific expression. Dysregulation of ECM1 is linked to pathologies. Loss-of-function mutations cause lipoid proteinosis, a rare autosomal recessive disorder characterized by skin and mucosal abnormalities. Conversely, ECM1 overexpression is associated with tumor progression in cancers (e.g., breast, liver) by promoting angiogenesis, metastasis, and immune evasion. It also serves as an autoantigen in lichen sclerosus, an inflammatory skin condition.
Recombinant ECM1 protein is produced via heterologous expression systems (e.g., mammalian cells, *E. coli*), enabling study of its biochemical functions and therapeutic potential. Purified recombinant ECM1 retains bioactivity, supporting in vitro and in vivo research on ECM remodeling, cancer biology, and regenerative medicine. It is instrumental in developing targeted therapies, such as monoclonal antibodies against ECM1 in oncology, and understanding its role in autoimmune diseases.
Overall, recombinant ECM1 serves as a vital tool for dissecting ECM-mediated cellular mechanisms and advancing translational applications in diverse diseases.
×
